Brian Robert Kovacevich

This inventor holds 68 USPTO granted patents and 17 published patent applications, plus 6 CIPO patents and 17 EPO patents, primarily in Biologic Therapeutics (CPC class C07K). Top assignees: Alderbio Holdings LLC, Systimmune, Inc., Darwin Discovery Limited. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian Robert Kovacevich. Retrieved from https://idiyas.com/inventor/brian-robert-kovacevich

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 68 (Patent Applications = 17)

% Patents Active = 70.6

CIPO Patents = 6 (Patent Applications = 6)

EPO Patents = 17 (Patent Applications = 30)

Average Co-Inventor Count = 8.5

ph-index = 17

Forward Citations = 976(Granted Patents)

Forward Citations (Not Self Cited) = 745(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Renton, WA (US) (2002 - 2017)
Redmond, WA (US) (2020)
Bellevue, WA (US) (2021)
Snohomish, WA (US) (2011 - 2024)

Company Filing History:

36 out of 98

Alderbio Holdings LLC

Darwin Discovery Limited

patents

4. 6 out of 7

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

patents

5. 4 out of 925

University of Iowa Research Foundation

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Sichuan Baili Pharmaceutical Co. Ltd.

13. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Tetravalent Antibodies

Anti-IL-6

Anti-CGRP

Multi-Specific Antibodies

Anti-PD-1

Anti-PD-L1

Guidance Proteins

Anti-NGF

Anti-CD3

Anti-ROR1

Autoimmunity

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12767722 - ANTI-4-1BB ANTIBODIES AND METHODS OF MAKING AND USING THEREOF (2026-10-20),

2. 12735487 - MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF (2026-09-15),

3. 12709647 - MULTI-SPECIFIC ANTIBODIES AND METHODS OF USING THEREOF (2026-08-18),

4. 12428483 - Bispecific tetravalent antibodies and methods of making and using thereof (2025-09-30),

5. 12384850 - Guidance and navigation control proteins and method of making and using thereof (2025-08-12),

6. 12029761 - Guidance and Navigation Control proteins and method of making and using thereof (2024-07-09),

7. 11987635 - Anti-4-1BB antibodies and methods of making and using thereof (2024-05-21),

8. 11827700 - Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies (2023-11-28),

9. 11787863 - Multi-specific antibodies and methods of making and using thereof (2023-10-17),

10. 11649286 - Tri-specific antibodies (2023-05-16),

11. 11560431 - Anti-PD-L1 antibodies and methods of making and using thereof (2023-01-24),

12. 11535667 - Anti-CD3 antibodies and methods of making and using thereof (2022-12-27),

13. 11518815 - Anti-ROR1 antibodies and methods of making and using thereof (2022-12-06),

14. 11466084 - Anti-PD-1 antibodies and methods of making and using thereof (2022-10-11),

15. 11325967 - Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light a version in subjects in need thereof, especially migraine sufferers (2022-05-10),

Title: Brian Robert Kovacevich: Innovator in Guidance and Navigation Control Protein Technologies

Introduction

Brian Robert Kovacevich, based in Snohomish, WA, is a prolific inventor with an impressive portfolio of 52 patents. His work primarily focuses on advancements in biotechnology, particularly in the realms of guidance and navigation control proteins which play a crucial role in immunotherapy and cancer treatment.

Latest Patents

Kovacevich's recent patents include groundbreaking technologies such as "Guidance and Navigation Control proteins and method of making and using thereof." This patent describes GNC proteins that include various binding domains for key T cell receptors and tumor associated antigens, optimizing immune responses against cancer. Another significant patent is "Anti-4-1BB antibodies and methods of making and using thereof," which covers monoclonal antibodies designed to enhance T-cell functionality in combating cancers and other disorders linked to T-cell dysfunction.

Career Highlights

Throughout his career, Brian has collaborated with innovative companies such as Alderbio Holdings LLC and Systimmune, Inc., furthering research and development in his field. His contributions bring forth new possibilities in the treatment of malignancies and immune challenges, showcasing his dedication to enhancing therapeutic strategies.

Collaborations

Brian’s innovative journey has been facilitated by partnerships with notable professionals including Leon F Garcia-Martinez and John A Latham. These collaborations have enriched his research, combining diverse expertise to tackle complex biomedical challenges.

Conclusion

In conclusion, Brian Robert Kovacevich stands out as a significant figure in the world of biotechnology innovation. His extensive patent portfolio and collaborative efforts position him at the forefront of medical advancements, making valuable contributions to the treatment of cancer and immune disorders. His ongoing work is poised to inspire further innovations in the field.

Profile summary based on public USPTO records.